{"id":48519,"date":"2025-11-18T11:23:06","date_gmt":"2025-11-18T03:23:06","guid":{"rendered":"https:\/\/flcube.com\/?p=48519"},"modified":"2025-11-18T11:23:07","modified_gmt":"2025-11-18T03:23:07","slug":"johnson-johnson-to-acquire-halda-therapeutics-for-3-05-b-deal-highlights-first%e2%80%91in%e2%80%91class-oral-riptac-hld%e2%80%910915","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48519","title":{"rendered":"Johnson\u202f&\u202fJohnson to Acquire Halda Therapeutics for $3.05\u202fB \u2013 Deal Highlights First\u2011in\u2011Class Oral RIPTAC HLD\u20110915"},"content":{"rendered":"\n

Johnson\u202f&\u202fJohnson (J&J, NYSE: JNJ<\/a>)<\/strong> announced a definitive agreement to acquire Halda Therapeutics<\/strong> in an all\u2011cash transaction valued at USD\u202f3.05\u202fbillion<\/strong>. The acquisition gives J&J immediate access to Halda\u2019s lead asset, HLD\u20110915<\/strong>, a first\u2011in\u2011class oral RIPTAC<\/strong> (Regulated Induced Proximity Targeting Chimeras) candidate for metastatic castration\u2011resistant prostate cancer (mCRPC)<\/strong>.<\/p>\n\n\n\n

Deal Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Johnson\u202f&\u202fJohnson (NYSE:\u202fJNJ)<\/td><\/tr>
Target<\/strong><\/td>Halda Therapeutics (private)<\/td><\/tr>
Transaction value<\/strong><\/td>USD\u202f3.05\u202fbillion<\/strong> cash<\/td><\/tr>
Closing timeline<\/strong><\/td>Expected Q2\u202f2026, subject to customary regulatory approvals<\/td><\/tr>
Strategic rationale<\/strong><\/td>Expand J&J\u2019s oncology pipeline with a novel oral small\u2011molecule platform and accelerate entry into the high\u2011growth mCRPC market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

HLD\u20110915 \u2013 Clinical & Mechanistic Highlights<\/h2>\n\n\n\n